Who is sponsoring NCT07184658?

NCT07184658 is sponsored by Kai Wang.

What drugs are being tested in NCT07184658?

Interventions in NCT07184658: Ultrasound-guided peritendinous saline injection.

What condition does NCT07184658 study?

NCT07184658 studies Tendon Adhesion.

Is NCT07184658 still recruiting?

NCT07184658 is currently recruiting now. Last updated 22 September 2025.

Last reviewed 2025-09-22 · How we verify

NCT07184658

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ultrasound-Guided Multiple Saline Injections for Prevention of Tendon Adhesion: A Randomized Controlled Trial

Recruiting now NA Last updated 22 September 2025

What this trial tests

NA trial testing Ultrasound-guided peritendinous saline injection in Tendon Adhesion in 136 participants. Currently enrolling.

Timeline

1 September 2025

Primary endpoint
31 January 2026

31 March 2026

Quick facts

Lead sponsor	Kai Wang
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	136
Start date	1 September 2025
Primary completion	31 January 2026
Estimated completion	31 March 2026
Sites	1 location across China

Drugs / interventions tested

Ultrasound-guided peritendinous saline injection

Conditions studied

Tendon Adhesion — all drugs for Tendon Adhesion →

Sponsor

Kai Wang

Who can join

Adults 18 to 60, any sex, with Tendon Adhesion. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This prospective randomized controlled trial aims to evaluate the efficacy and safety of ultrasound-guided repeated normal saline injections for the prevention and treatment of tendon adhesion following flexor tendon repair. Tendon adhesion is a common complication after tendon injury, leading to pain, stiffness, and impaired hand function. Conventional anti-adhesion strategies, such as physical barrier membranes, may induce local inflammation or have limited effectiveness. In this study, patients undergoing tendon repair will be randomly assigned to receive either ultrasound-guided peritendinous saline injections at 7, 14, and 21 days after surgery (intervention group) or no injection (control group). The primary outcome is total active motion (TAM-%) at 3 months after surgery. Secondary outcomes include TAM-% at 6 weeks, pain scores (VAS), Michigan Hand Questionnaire (MHQ) scores, infection rate, and tendon rupture rate. A total of 136 patients will be enrolled (68 in each group). The findings of this trial will help to establish whether repeated saline injections under ultrasound guidance can effectively prevent tendon adhesion, improve pain and functional outcomes, and ensure tendon healing with minimal complications.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07184658 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Kai Wang
Last refreshed: 22 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07184658.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing